Advocacy groups form a buyer’s club to obtain generic versions of pricey Vertex cystic fibrosis drug
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Zacks Investment Research on MSN
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
We expect Vertex Pharmaceuticals VRTX to surpass expectations when it reports its third-quarter 2025 results on Nov. 3, after ...
Abstract: Anomaly detection is a fundamental task in hyperspectral image (HSI) processing. However, most existing methods rely on pixel feature vectors and overlook the relational structure ...
The All India Institute of Medical Sciences (AIIMS), New Delhi, has opened the form correction window for the INI CET 2026 January session on its official website - aiimsexams.ac.in. Candidates who ...
(NYSE: CALX) today announced the next generation of the Calix Broadband Platform, fully evolved for agentic AI and purpose-built to address the workflow, data, security, and insight requirements of ...
Abstract: Graph scattering transform (GST) is mathematically-designed graph convolutional model that iteratively applies graph filter banks to achieve comprehensive feature extraction from graph ...
Multi-agent explanatory AI: turns hybrid retrieval (Elasticsearch) into sourced causal chains with a graph view and LLM-backed summarization (Vertex AI / Gemini). Ships with a FastAPI backend and ...
Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.
Vertex Pharmaceuticals chief Reshma Kewalramani said AI could reduce the time spent on drug-approval paperwork from months to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback